The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.
 
Hironobu Hashimoto
No Relationships to Disclose
 
Masakazu Abe
No Relationships to Disclose
 
Masahiko Nakao
No Relationships to Disclose
 
Hideaki Mizutani
No Relationships to Disclose
 
Yasuhiko Sakata
No Relationships to Disclose
 
Yukiyoshi Fujita
No Relationships to Disclose
 
Tomoyasu Nishimura
No Relationships to Disclose
 
Katsuya Hirano
No Relationships to Disclose
 
Hideaki Okada
No Relationships to Disclose
 
Naoki Inui
No Relationships to Disclose
 
Yukio Sakata
No Relationships to Disclose
 
Hirotoshi Iihara
No Relationships to Disclose
 
Sadamoto Zenda
No Relationships to Disclose
 
Yosuke Uchitomi
No Relationships to Disclose
 
Takuhiro Yamaguchi
No Relationships to Disclose
 
Yukari Hoshina
No Relationships to Disclose
 
Takako Yanai
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Ignyta (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Expert Testimony - AstraZeneca; Ono Pharmaceutical